Elotuzumab in Patients With Multiple Myeloma Before and After Peripheral Stem Cell Autologous Graft
Status:
Withdrawn
Trial end date:
2019-01-15
Target enrollment:
Participant gender:
Summary
This is a multicenter, open-label phase II study, assessing the efficacy of elotuzumab in
elderly patients with multiple myeloma undergoing peripheral stem cell autologous graft